Promis Neurosciences and NeuroPace see updated analyst earnings estimates

Analysts have issued updated earnings per share (EPS) estimates for two neuroscience-focused companies.

Brookline Capital Markets raised its Q3 2026 EPS forecast for Promis Neurosciences to ($1.29) from a previous estimate of ($2.41). The firm maintains a “Strong-Buy” rating on the stock. Promis Neurosciences recently reported Q3 earnings of ($1.28) per share, which exceeded the consensus estimate of ($1.38).

Conversely, HC Wainwright lowered its Q3 2027 EPS estimate for NeuroPace to $0.05 per share, down from a prior forecast of $0.06. Despite the reduction, HC Wainwright maintains a “Buy” rating on NeuroPace with a $20.00 price objective.